| 前收市價 | 8.63 |
| 開市 | 8.57 |
| 買盤 | 8.43 x 1100 |
| 賣出價 | 8.87 x 800 |
| 今日波幅 | 8.31 - 8.74 |
| 52 週波幅 | 2.15 - 14.48 |
| 成交量 | |
| 平均成交量 | 262,559 |
| 市值 | 309.028M |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.94 |
| 業績公佈日 | 2023年5月02日 - 2023年5月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 18.18 |
- Insider Monkey
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may […]
- Benzinga
Rain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity
Rain Therapeutics Inc (NASDAQ: RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. "Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll," said Avanish Vellanki, co-founder & CEO. Seventeen patients have been enrolled, 15 of whom have been dosed with milademetan. Ten
- Benzinga
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ: RAIN), with a price target of $10 with a Buy rating. With an upside of almost 60%, the analyst believes Rain's lead asset, milademetan, has the potential to become a tumor-agnostic therapy for MDM2 amplified cancers. Milademetan, in-licensed from Daiichi Sankyo (OTC: DSNKY) in 2020, is an oral MDM2 inhibitor that reactivates the tumor suppressor gene, p53. P53 is a key regulator of various cellular processes, including the cell c
